Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 16/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL58645 | 0.90 | ACVRL1 (0.61) | ACVRL1PIK3CDMERTK | |
| SCHEMBL56767 | 0.85 | ACVRL1 (0.58) | ACVRL1PIK3CDMERTKMAP4K4 | |
| SCHEMBL2635291 | 0.82 | ACVRL1 (0.53) | ACVRL1MERTK | |
| SCHEMBL66554 | 0.80 | ACVRL1 (0.49) | ACVRL1PIK3CDMERTK | |
| SCHEMBL59022 | 0.80 | ACVRL1 (0.59) | ACVRL1PIK3CDMERTK | |
| SCHEMBL90826 | 0.77 | ACVRL1 (0.49) | ACVRL1MERTKMAP4K4 | |
| SCHEMBL57965 | 0.77 | FLT3 (0.59) | ACVRL1MAP4K4 | |
| SCHEMBL276256 | 0.75 | FGFR1 (0.49) | ACVRL1PIK3CDMERTK | |
| SCHEMBL27768106 | 0.74 | ACVRL1 (0.61) | ACVRL1MERTK | |
| SCHEMBL90935 | 0.74 | KDR (0.51) | ACVRL1MERTKMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143393-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | CDK4, CDKL4, MKI67 | ACVRL1 963/4885PIK3CD 608/4885MERTK 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.